The U.S. Food and Drug Administration (FDA) has just approved, Qbrexza, a new treatment for the condition otherwise known as primary axillary hyperhidrosis.
The U.S. Food and Drug Administration (FDA) has just approved, Qbrexza, a new treatment for the condition otherwise known as primary axillary hyperhidrosis.